<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02301208</url>
  </required_header>
  <id_info>
    <org_study_id>JiangsuCIH</org_study_id>
    <nct_id>NCT02301208</nct_id>
  </id_info>
  <brief_title>Weekly Cisplatin or Nedaplatin Concurrent With Intensity-modulated Radiation Therapy in Nasopharyngeal Carcinoma</brief_title>
  <acronym>NPC-RCT-WCRT</acronym>
  <official_title>A Randomized Phase III Study of Concurrent Weekly Nedaplatin or Cisplatin With IMRT in NPC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>He Xia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Cancer Institute &amp; Hospital</source>
  <brief_summary>
    <textblock>
      This is a randomized Phase III study to evaluate efficancy of weekly cisplatin or nedaplatin
      concurrent with Intensity-modulated radiation therapy in Nasopharyngeal Carcinoma (NPC).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progress-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response</measure>
    <time_frame>radiotherapy in 2 week、4 week、7 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Low dose cisplatin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemotherapy: cisplatin 20mg/m2,weekly,for 6 cycles during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose cisplatin arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>concurrent chemotherapy: cisplatin 30mg/m2,weekly,for 6 cycles during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose nedaplatin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent chemotherapy: nedaplatin 20mg/m2,weekly,for 6 cycles during radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose nedaplatin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>concurrent chemotherapy: nedaplatin 30mg/m2,weekly,for 6 cycles during radiotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>Nedaplatin combine with IMRT</description>
    <arm_group_label>Low dose nedaplatin arm</arm_group_label>
    <arm_group_label>High dose nedaplatin arm</arm_group_label>
    <other_name>NDP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin combine with IMRT</description>
    <arm_group_label>Low dose cisplatin arm</arm_group_label>
    <arm_group_label>High dose cisplatin arm</arm_group_label>
    <other_name>PDD</other_name>
    <other_name>DDP</other_name>
    <other_name>CDDP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed untreated NPC patients

          -  T1-2N1-3M0 or T3-4NxM0

          -  18-70 years old

          -  with MRI examinations

          -  ECOG ≤ 2

          -  With written consent

        Exclusion Criteria:

          -  With a second cancer

          -  Pregnancy

          -  With other severe diseases (blood,liver ,kidney or heart diseases)

          -  Could not be staged properly

          -  Without written consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Li Yin, M.D. Ph.D.</last_name>
    <phone>+8613913909043</phone>
    <email>yinli7878@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pengwei Yan, M.M.</last_name>
    <phone>+8613815888775</phone>
    <email>179032794@qq.com</email>
  </overall_contact_backup>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2014</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Jiangsu Cancer Institute &amp; Hospital</investigator_affiliation>
    <investigator_full_name>He Xia</investigator_full_name>
    <investigator_title>Jiangsu Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nedaplatin</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

